Tesamorelin and Levothyroxine: What the Current Evidence Shows

The easy answer would be to convert growth-hormone physiology into a rigid interaction protocol. The evidence does not support that move. Tesamorelin stimulates endogenous growth hormone, and growth hormone can affect thyroid physiology in other populations. But a plausible pathway is not the same thing as a demonstrated tesamorelin–levothyroxine interaction.

The useful question is narrower: what does the current tesamorelin record actually show, what was never tested, and which monitoring rules belong to levothyroxine regardless?

The Label–Mechanism Evidence Adjudication

This table is the core distinction the previous article missed: no documented label interaction is not identical to proof of no possible biological influence. Both statements can be true at once.

What the Current Tesamorelin Label Says

EGRIFTA WR is FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. It is not approved for general weight management. The current label says tesamorelin increases growth hormone, IGF-1, and IGFBP-3, while reporting:

“No clinically significant changes in the levels of other pituitary hormones, including thyroid-stimulating hormone (TSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH) and prolactin, were observed”

That is the FDA-approved label's clinical-trial summary, not an endorsement of combining products. The precise source is DailyMed's current EGRIFTA WR label, section 12.2, Pharmacodynamics, revised March 2025 and posted as the current structured product label.

The same label's interaction section focuses on two different issues:

• Growth hormone may alter clearance of some drugs metabolized through CYP450 pathways, so the label advises monitoring with those substrates.
• Growth hormone inhibits 11β-HSD1, which can matter for people receiving glucocorticoid replacement.

Levothyroxine is not presented as either interaction. The label also reports dedicated pharmacokinetic evaluations with simvastatin and ritonavir, but not with levothyroxine. That makes “not directly studied” the responsible boundary—not “moderate interaction,” “expected thyroid suppression,” or “dose increase likely.”

For the broader labeled interaction record, see HealthRX.com's tesamorelin drug-interaction overview. The tesamorelin–rosuvastatin analysis addresses a different question and should not be used as a substitute for thyroid evidence.

Why the Mechanism Still Comes Up

Tesamorelin is a growth hormone-releasing hormone analog. Growth hormone research outside the tesamorelin indication has shown that thyroid measures can shift under some conditions. In a controlled human experiment, growth hormone administration increased extrathyroidal conversion of T4 to T3 and suppressed circulating thyrotropin (Jørgensen et al., 1994). Studies of adults receiving direct growth-hormone replacement have also described unmasking or changing thyroid replacement needs in selected patients (Porretti et al., 2002).

Those findings are relevant background, but the evidence-transfer limits matter:

1. Direct growth-hormone replacement is not the same intervention as tesamorelin.
2. Growth-hormone-deficient populations are not the same population as adults with HIV-associated lipodystrophy.
3. A change in a laboratory hormone is not automatically a clinically important drug interaction.
4. Neither study establishes how often levothyroxine must be adjusted after tesamorelin.

The current tesamorelin label's observed TSH result therefore deserves more weight for this precise question than an extrapolated mechanism alone.

The Practical Decision: Do Not Adjust a Dose on Theory

There is no evidence-based universal tesamorelin–levothyroxine adjustment. In particular, the record does not support the previous page's claims that people should expect a 12.5-to-25-microgram increase, that roughly one-third to one-half will need an adjustment, or that every patient needs a new three-month testing schedule. Those figures were transferred from other settings and presented as though they described this combination.

Instead, separate three decisions.

1. How should levothyroxine be taken?

Follow the instructions for the prescribed levothyroxine product. Current U.S. labeling generally emphasizes consistent administration on an empty stomach and spacing from agents that impair absorption, such as calcium or iron. Tesamorelin is injected and is not identified as a levothyroxine absorption blocker. Separating the injection from the tablet by several hours has no demonstrated interaction-prevention benefit.

If absorption is the concern, HealthRX.com's levothyroxine and calcium guide covers an interaction with an actual binding mechanism.

2. When should thyroid labs be checked?

Use the thyroid condition and levothyroxine treatment history. Current DailyMed labeling says adults with primary hypothyroidism should have TSH assessed 6 to 8 weeks after a levothyroxine dosage change, then every 6 to 12 months when stable, and when clinical status changes (Levothyroxine Sodium Tablets, section 2.4).

Starting tesamorelin is not itself a levothyroxine dose change. A clinician may reasonably obtain or repeat thyroid tests when the patient's thyroid disease is unstable, symptoms change, adherence or absorption changes, or another clinical factor makes the result useful. That is individualized thyroid management—not a tesamorelin-specific mandate.

For the general distinction between routine and problem-driven follow-up, see levothyroxine monitoring and tesamorelin monitoring.

3. When should the prescriber be contacted sooner?

Contact the prescribing team if there is a material change in symptoms associated with under- or over-replacement, a new levothyroxine dose or formulation, inconsistent dosing, a new absorption-interfering medicine or supplement, pregnancy, or an unexpected thyroid result. These triggers matter whether or not tesamorelin is present.

Do not self-adjust either medicine based on weight, energy, or a single unconfirmed laboratory value.

A Five-Question Chart Review

When both medicines appear on the list, this short review is more useful than assigning an unsupported interaction severity:

1. Is tesamorelin being used for its labeled population and purpose? The evidence base is adults with HIV-associated lipodystrophy, not general obesity treatment.
2. Why is levothyroxine prescribed? Primary hypothyroidism, central hypothyroidism, pregnancy, and TSH suppression do not use identical monitoring targets.
3. Are the thyroid values stable before the combination begins? Instability should be explained rather than automatically attributed to tesamorelin.
4. Did anything else change? Timing, food, calcium, iron, proton-pump inhibitors, biotin, adherence, brand/formulation, and illness can all complicate interpretation.
5. Would a result change management? Order a test when its timing and clinical context make it interpretable.

This framework avoids two opposite errors: dismissing a patient's thyroid history because the label is reassuring, or turning a theoretical mechanism into a made-up dose protocol.

What This Page Cannot Tell You

No dedicated tesamorelin–levothyroxine interaction trial was identified in the current FDA label or the primary tesamorelin trial record. The label's pituitary-hormone statement describes group-level clinical-trial observations; it cannot guarantee that an individual person's TSH will never change. Direct growth-hormone studies provide biological context but do not quantify the risk for this exact combination.

Medical review of this revision is pending. The evidence synthesis is implementation-ready, but it is not a personalized dosing recommendation and does not represent completed HealthRX.com physician review.